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Background/Objective: The prevalence of selected psychiatric disorders, such as depression and anxiety,
is higher in patients with psoriasis. However, the association between psoriasis and schizophrenia is less
clear. Here, we investigated whether the prevalence of schizophrenia is higher in patients with psoriasis.
Methods: In this cross-sectional study, we analyzed the 1-million-person cohort enrolled from Taiwan's
National Health Insurance Research Database. Psoriasis, schizophrenia, and comorbidities were ascer-
tained by the International Classiﬁcation of Diseases, 9th revision, Clinical Modiﬁcation coding. For
schizophrenia, the concomitant catastrophic illness certiﬁcate was used to verify the diagnosis. The
prevalence of schizophrenia in patients with psoriasis was compared with the prevalence of schizo-
phrenia in a comparable population using a generalized linear mixed model.
Results: The prevalence of schizophrenia was signiﬁcantly higher in patients with psoriasis than in the
comparison population [prevalence ratio ¼ 1.77, 95% conﬁdence interval (CI) ¼ 1.48e2.12, p < 0.0001)].
Within the psoriasis cohort, patients aged between 40 years and 59 years had a higher odds ratio (OR) for
schizophrenia (OR ¼ 2.49, 95% CI ¼ 1.55e4.00, p ¼ 0.0002). Furthermore, psoriatic patients with co-
morbid cerebrovascular disease (OR ¼ 2.01, 95% CI ¼ 1.11e3.65, p ¼ 0.0220) and chronic pulmonary
disease (OR ¼ 1.64, 95% CI ¼ 1.07e2.49, p ¼ 0.0218) had higher odds for schizophrenia.
Conclusion: Schizophrenia is more prevalent in patients with psoriasis. Although the exact mechanisms
remain to be clariﬁed, the ﬁnding that psoriatic patients with comorbid cerebrovascular disease or chronic
pulmonarydiseasehavehigherodds for schizophreniamay implypsoriatic patientswith those comorbidities
are likely to have higher inﬂammatory burden,whichwould contribute to the development of schizophrenia
if a disruption of the bloodebrain barrier is present. Further investigations are indicated to validate the hy-
pothesis explaining the association between known comorbidies of psoriasis and schizophrenia.
Copyright © 2016, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Psoriasis is a chronic inﬂammatory disease affecting the skin and
joints.1 The itch and pain caused by the skin and joint lesions affecty have no ﬁnancial or non-
atter or materials discussed
tology, Kaohsiung Medical
ty, 100 Tzyou First Road,
al Association. Published by Elsevipatient quality of life.2e4 Moreover, the appearance of skin lesions
often have negative impacts on patient psychological and social
functions.5,6 A growing body of literature indicates that psychiatric
disorders are more prevalent in patients with psoriasis.7e9 In pso-
riatic patients, the prevalence of depression is estimated to be
15.4%.10 Another study reported that pediatric patients with pso-
riasis have higher risks of developing depression and anxiety.7 The
higher prevalence of depression and anxiety in psoriatic patients
may be attributed to discomforts caused by inﬂammation and
discomﬁture caused by visible skin lesions.
The association between psoriasis and schizophrenia has not
been well-established. A study reported that psoriatic patients areer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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antipsychotics.7 However, Chen et al11 indicated that the odds ratio
(OR) of psoriasis is 1.60 in male patients with schizophrenia, while
the OR of psoriasis is not signiﬁcantly higher in female patients
with schizophrenia. Another nationwide population-based study
conducted in Taiwan showed female patients, but not male pa-
tients, with schizophrenia have increased risk of psoriasis.12 Given
these conﬂicting results, the association between psoriasis and
schizophrenia remains to be clariﬁed.Methods
Data source
The Taiwan government launched the compulsory National Health
Insurance (NHI) program in 1995, with ~98% of Taiwanese residents
now enrolled in the NHI program. Medical records, including
patient-demographic characteristics, diagnoses, healthcare utili-
zation, and expenses, are included in the NHI program. The Inter-
national Classiﬁcation of Diseases, 9th revision, Clinical
Modiﬁcation (ICD-9-CM) is used to record diagnoses in the NHI
program. To ensure the reliability of ICD-9-CM coding in the NHI
program, the Bureau of Taiwan performed random checking and
imposed ﬁnes for false claims. The NHI Research Database (NHIRD)
includes claim data from the NHI program. The NHIRD ensures
enrollee conﬁdentiality through assigning an anonymous code to
each enrollee. The accuracy of ICD-9-CM coding in the NHIRD was
previously validated.13,14 NHIRD is further classiﬁed into several
data subsets for different research purposes. In this study, we used
the “Longitudinal Health Insurance Database 2010” (LHID 2010),
which is a NHIRD data subset containing longitudinal data of
1,000,000 enrollees randomly sampled from 2010. This study was
approved by the Institutional Review Board of the Kaohsiung
Medical University Hospital, Kaohsiung, Taiwan.Study population
We analyzed the 1-million-person cohort enrolled in the LHID 2010
database and excluded people < 20-years old (born after January 1,
1990) and people > 100-years old (born before January 1, 1910). The
study cohort (psoriatic patients) was composed of enrolleesFigure 1 Algorithm of studdiagnosed with psoriasis or psoriatic arthritis during the period
from January 1, 1997 to December 31, 2010, while the population
comparisons (nonpsoriatic patients) consisted of enrollees who had
not been diagnosed with psoriasis or psoriatic arthritis during the
study period.
Patient ascertainment was determined based on the ICD-9-CM
codes. Patients with psoriasis were deﬁned as enrollees docu-
mented with ICD-9-CM codes 696.0, 696.1, or 696.8 one or more
times during the study period. These codes have been used in
psoriasis studies using the NHIRD.15e17 We identiﬁed 10,796 pso-
riatic patients and 767,327 individuals for the comparison popu-
lation. Additionally, age-group and sex-matched comparisons were
further allocated to psoriatic patients with a ratio of 1:1. Figure 1
shows the algorithm associated with study population selection.Construction of variables
The primary outcome of our interest was schizophrenia. Patients
with schizophrenia were deﬁned as enrollees documented with
ICD-9-CM code 295 one time or more and held a catastrophic
illness certiﬁcate due to schizophrenia during the study period.
Certiﬁcation of catastrophic illness is strict in Taiwan, and cata-
strophic illnesses are deﬁned by the Department of Health and
Welfare of the Taiwan Government. If a patient is diagnosed with a
disease classiﬁed as a catastrophic illness by at least one specialist,
the patient can submit supporting documents to apply for a cata-
strophic illness certiﬁcate. Once approved, the catastrophic illness
of the patient will be registered by the NHI program, and the pa-
tient can waive copayment for related conditions for future inpa-
tient and outpatient care.
Covariates included age, sex, and comorbidities. Age was strat-
iﬁed into three age groups, including 20e39 years, 40e59 years,
and  60 years. Each comorbidity was ascertained by ICD-9-CM
codes documented over three times during the study period.
The ICD-9-CM codes for each comorbidity have been adopted in
previous studies.14,18Statistical analysis
In this cross-sectional study, prevalence of schizophrenia and 95%
conﬁdence interval (CI) in psoriatic patients and the comparisony population selection.
H.-P. Tu et al. / Dermatologica Sinica 35 (2017) 1e6 3population were estimated by a generalized linear mixed model
and assuming a Poisson distribution. The prevalence ratio (PR) was
calculated and compared between psoriatic patients and the
comparison population by using a log-binomial model. Within
psoriatic patients, the crude and adjusted ORs of factors were
calculated using a multiple logistic regression model. For univariate
analysis, c2 and t tests were used for categorical and continuous
variables, respectively.
We used the Joinpoint Regression Program (version 4.2.0.2;
National Cancer Institute, Bethesda, MD, USA; http://surveillance.
cancer.gov/joinpoint/) to estimate trends in the prevalence of
schizophrenia in psoriatic patients and the comparison population.
The Joinpoint Regression Program is statistical software used for
the analysis of trends using joinpoint models. The annual percent
change indicates the magnitude of the trend for each time period.
We used the Joinpoint program to estimate trends in the prevalence
of schizophrenia in each calendar year from 2000 to 2010.Results
Characteristics of psoriatic patients and the comparison
population
Characteristics of the study population are shown in Table 1. There
were 10,796 patients who met the inclusion criteria of psoriasis.
The comparison population was composed of 767,327 people, with
signiﬁcant differences in age and gender between psoriatic patients
and the comparison population. Comorbidities, including myocar-
dial infarction, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, chronic pulmonary disease, rheumatologic
disease, liver disease, diabetes, hemiplegia or paraplegia, and renal
disease, were signiﬁcantly more common in psoriatic patients than
in the comparison population.Prevalence of schizophrenia in psoriatic patients and the
comparison population
The prevalence of schizophrenia was signiﬁcantly higher in psori-
atic patients than in the comparison population (Table 2). The
prevalence ratio was 1.77 (95% CI ¼ 1.48e2.12, p < 0.0001). WhenTable 1 Demographic characteristics of patients with psoriasis and the comparison
population.
Patients with
psoriasis
Population
comparison
P
n 10,796 767,327
Age, y, mean (SD) 50.5 (17.8) 45.9 (16.5) <0.0001
Age group, n (%)
20e39 3517 (32.6) 317,559 (41.4)
40e59 4140 (38.3) 299,448 (39.0)
60 3139 (29.1) 150,320 (19.6) <0.0001
Gender, n (%)
Males 5961 (55.2) 371,042 (48.4)
Females 4835 (44.8) 396,285 (51.6) <0.0001
Comorbidities, n (%)
Myocardial infarction 69 (0.6) 3393 (0.4) 0.0014
Congestive heart failure 565 (5.2) 20,734 (2.7) <0.0001
Peripheral vascular disease 395 (3.7) 16,908 (2.2) <0.0001
Cerebrovascular disease 1033 (9.6) 42,001 (5.5) <0.0001
Chronic Pulmonary Disease 2486 (23) 112,375 (14.6) <0.0001
Rheumatologic disease 483 (4.5) 16,778 (2.2) <0.0001
Liver disease 2470 (22.9) 111,368 (14.5) <0.0001
Diabetes 1684 (15.6) 70,661 (9.2) <0.0001
Hemiplegia or paraplegia 223 (2.1) 8772 (1.1) <0.0001
Renal disease 447 (4.1) 16,005 (2.1) <0.0001
SD ¼ standard deviation.further stratiﬁed by age group, psoriatic patients > 40-years old
exhibited signiﬁcantly higher prevalence of schizophrenia than
members of the comparison group. The prevalence ratio was
signiﬁcantly higher in both males (prevalence ratio ¼ 1.59, 95%
CI ¼ 1.24e2.04, p ¼ 0.0003) and females (prevalence ratio ¼ 1.99,
95% CI ¼ 1.54e2.58, p  0.0001). When further stratiﬁed by
comorbidities, psoriatic patients with cerebrovascular disease,
chronic pulmonary disease, and liver disease exhibited a higher
prevalence of schizophrenia as compared with the comparison
group. In the age-group and sex-matched model, psoriatic patients
also showed higher adjusted OR of schizophrenia (OR ¼ 1.44, 95%
CI ¼ 1.08e1.92, p ¼ 0.0122) as compared with controls (Table S1).
ORs of factors for schizophrenia in psoriatic patients
Within the psoriatic cohort, patients aged between 40 years and
59 years exhibited higher adjusted OR (OR ¼ 2.49, 95%
CI ¼ 1.55e4.00, p ¼ 0.0002) for schizophrenia (Table 3). There was
no statistically signiﬁcant difference in risk of schizophrenia be-
tween male and female psoriatic patients. The adjusted ORs of
psoriatic patients with cerebrovascular disease and chronic pul-
monary disease were 2.01 (95% CI¼ 1.11e3.65, p¼ 0.0220) and 1.64
(95% CI ¼ 1.07e2.49, p ¼ 0.0218), respectively.
Prevalence trend of schizophrenia in patients with psoriasis
and in the comparison population
Figure 2 shows the temporal trend in prevalence of schizophrenia
from 2000 to 2010. The prevalence of schizophrenia increased from
0.39% to 1.10% in psoriatic patients and from 0.31% to 0.47% in the
comparison population, respectively. The prevalence of schizo-
phrenia from 2000 to 2010 in patients with psoriasis was signiﬁ-
cantly different from that observed in the comparison population
(p < 0.0001).
The average annual percentage change (AAPC) of the prevalence
for schizophrenia was 13.9 (95% CI ¼ 7.4e20.8, p ¼ 0.0007) in
psoriatic patients and was 4.3 (95% CI ¼ 4.2e4.4, p < 0.0001) in the
comparison population from 2000 to 2010 (Table 4). The AAPC of
schizophrenia was signiﬁcantly higher in the psoriatic group as
compared with that observed in the comparison population (AAPC
difference ¼ 9.6, 95% CI ¼ 3.9e15.4, p < 0.05).
Discussion
While previous research showed conﬂicting results regarding as-
sociations between schizophrenia and psoriasis,7,11,12 our study
showed that the prevalence of schizophrenia is higher in both male
and female psoriatic patients. The prevalence ratios were signiﬁ-
cantly higher in psoriatic patients > 40-years old and in psoriatic
patients with comorbidities, including cerebrovascular disease,
chronic pulmonary disease, and liver disease. Within psoriatic pa-
tients, older age, cerebrovascular disease, and chronic pulmonary
disease exhibited higher odds for schizophrenia. Although the
trends of schizophrenia increased in both the psoriatic cohort and
the general population from 2000 to 2010 (Figure 2 and Table 4),
the trend in the psoriatic cohort was signiﬁcantly higher (AAPC
difference ¼ 9.6, p < 0.05).
Psoriasis is a chronic immune-mediated disease involving sys-
temic inﬂammation.19e21 T helper 17 (Th17) cells and proin-
ﬂammatory cytokines, such as tumor necrosis factor-a, play a
crucial role in the microenvironment of psoriasis.19 Th17 cells and
proinﬂammatory cytokines are also involved in the pathogenesis of
schizophrenia.22e24 Activation of Th17 cells occurs in patients with
drug-naive, ﬁrst-episode schizophrenia.25 Given that psoriatic pa-
tients with cerebrovascular disease exhibit increased ORs for
Table 2 Prevalence of schizophrenia in psoriatic patients and the comparison population.a
Psoriasis Population comparison Psoriasis vs.
comparison
population
p
Schizophrenia, n At risk
population, n
Prevalence %
(95% CI)
schizophrenia, n At risk
population, n
Prevalence
% (95% CI)
Prevalence ratio
(95% CI)
Total 121 10796 1.12 (0.94e1.34) 4853 767,327 0.63 (0.61e0.65) 1.77 (1.48e2.12) <0.0001
Age group (y)
20e39 24 3517 0.68 (0.46e1.02) 1576 317,559 0.50 (0.47e0.52) 1.38 (0.92e2.05) 0.1203
40e59 74 4140 1.79 (1.42e2.24) 2578 299,448 0.86 (0.83e0.89) 2.08 (1.65e2.61) <0.0001
60 23 3139 0.73 (0.49e1.10) 699 150,320 0.47 (0.43e0.50) 1.58 (1.04e2.38) 0.0313
Gender
Males 63 5961 1.06 (0.83e1.35) 2466 371,042 0.66 (0.64e0.69) 1.59 (1.24e2.04) 0.0003
Females 58 4835 1.20 (0.93e1.55) 2387 396,285 0.60 (0.58e0.63) 1.99 (1.54e2.58) <0.0001
Comorbidities
Myocardial infarction 0 69 e 8 3393 0.24 (0.12e0.47) 0(0e.) 0.9998
Congestive heart failure 3 565 0.53 (0.17e1.65) 132 20,734 0.64 (0.54e0.76) 0.83 (0.27e2.61) 0.7553
Peripheral vascular disease 2 395 0.51 (0.13e2.02) 95 16,908 0.56 (0.46e0.69) 0.90 (0.22e3.64) 0.8839
Cerebrovascular disease 17 1033 1.65 (1.02e2.65) 335 42,001 0.80 (0.72e0.89) 2.06 (1.27e3.35) 0.0033
Chronic pulmonary disease 36 2486 1.45 (1.04e2.01) 991 112,375 0.88 (0.83e0.94) 1.64 (1.18e2.28) 0.0032
Rheumatologic disease 4 483 0.83 (0.31e2.21) 103 16,778 0.61 (0.51e0.74) 1.35 (0.50e3.65) 0.5553
Liver disease 33 2470 1.34 (0.95e1.88) 955 111,368 0.86 (0.80e0.91) 1.56 (1.10e2.20) 0.0117
Diabetes 24 1684 1.43 (0.96e2.13) 703 70,661 0.99 (0.92e1.07) 1.43 (0.96e2.15) 0.0812
Hemiplegia or paraplegia 5 223 2.24 (0.93e5.39) 82 8772 0.93 (0.75e1.16) 2.40 (0.98e5.86) 0.0548
Renal disease 5 447 1.12 (0.47e2.69) 106 16,005 0.66 (0.55e0.8) 1.69 (0.69e4.12) 0.2495
CI ¼ conﬁdence interval.
a Prevalence with 95% CI was estimated by a generalized linear mixed model assuming a Poisson distribution. Prevalence ratio with 95% CI was estimated by the log-
binomial model.
Table 3 Crude and adjusted OR of factors associated with prevalence of schizophrenia in persons with psoriasis.a
Crude OR (95% CI) p Adjusted OR (95% CI) p
Age group (y)
20e39 1.00 1.00
40e59 2.65 (1.67e4.21) <0.0001 2.49 (1.55e4.00) 0.0002
60 1.07 (0.61e1.91) 0.8067 0.79 (0.41e1.51) 0.4676
Gender
Males
Females 1.14 (0.79e1.63) 0.4839 1.26 (0.87e1.81) 0.2197
Comorbidities
Congestive heart failure 0.46 (0.15e1.44) 0.1823 0.42 (0.13e1.37) 0.1490
Peripheral vascular disease 0.44 (0.11e1.79) 0.2505 0.39 (0.09e1.63) 0.1981
Cerebrovascular disease 1.55 (0.93e2.61) 0.0945 2.01 (1.11e3.65) 0.0220
Chronic pulmonary disease 1.42 (0.96e2.10) 0.0787 1.64 (1.07e2.49) 0.0218
Rheumatologic disease 0.73 (0.27e1.98) 0.5346 0.64 (0.23e1.77) 0.3912
Liver disease 1.27 (0.85e1.90) 0.2480 1.08 (0.71e1.65) 0.7156
Diabetes 1.34 (0.86e2.11) 0.1973 1.33 (0.82e2.18) 0.2491
Hemiplegia or paraplegia 2.07 (0.84e5.11) 0.1153 1.62 (0.63e4.19) 0.3193
Renal disease 1.00 (0.41e2.46) 0.9964 0.97 (0.38e2.47) 0.9482
Psoriasis duration, n (%)
 5 y
5e10 y 0.76 (0.51e1.14) 0.1891 0.74 (0.50e1.12) 0.1533
> 10 y 0.89 (0.55e1.44) 0.6425 0.87 (0.54e1.41) 0.5736
CI ¼ conﬁdence interval; OR ¼ odds ratio.
a Crude OR was calculated using a logistic regression model. Adjusted OR of factors in table with prevalence of schizophrenia in psoriasis patients were calculated using a
multiple logistic regression model.
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brain barrier in psoriatic patients would activate the Th17 pathway
in the brain, thereby potentiating susceptibility to schizophrenia.
This possibility also explains why only psoriatic patients > 40-yearsTable 4 The AAPC of the prevalence for schizophrenia in psoriatic patients and the com
Cohort AAPC 95% CI
Schizophrenia in psoriasis 13.9 7.4e20.8
Schizophrenia in population comparison 4.3 4.2e4.4
AAPC ¼ average annual percentage change; CI ¼ conﬁdence interval.
a The Joinpoint Regression Program (version 4.2.0.2) was used to calculate trends in t
ulation. The AAPC from 2000 to 2010 in the two cohorts was signiﬁcantly different.old, who exhibit higher risks of cerebrovascular disease, have a
higher prevalence of schizophrenia as compared with the com-
parison group. Further investigations are required to verify this
hypothesis.parison population from 2000 to 2010.a
p AAPC difference 95% CI p
0.0007 9.6 3.9e15.4 <0.05
<.0001
he prevalence of schizophrenia in patients with psoriasis and the comparison pop-
Figure 2 Temporal trend of prevalence of schizophrenia in patients with psoriasis and the comparison population. Data shows the temporal trend in prevalence of schizophrenia
from 2000 to 2010. The prevalence of schizophrenia in patients with psoriasis was signiﬁcantly higher than that observed in the comparison population (p < 0.0001).
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ease exhibit increased ORs relative to those without chronic pul-
monary disease remains to be clariﬁed. It is possible that psoriatic
patients with comorbid lung disease have a dysregulated immune
response that is involved in both psoriasis and schizophrenia.
Additionally, methotrexate use may increase the risk of lung dis-
eases.26e28 It is possible that psoriatic patients with chronic pul-
monary disease reﬂected those with severe psoriasis and receiving
methotrexate treatment. Whether methotrexate use in psoriatic
patients is associated with the higher prevalence is unclear. Further
study is needed to elucidate potential associations between
methotrexate use, psoriasis, and schizophrenia.
Notably, in psoriatic patients, the presentation of schizophrenia
is more prevalent in women and those aged > 40-years. Generally,
schizophrenia is more common in men than inwomen, with a ratio
of 1.4:1, andwomen tend to experience disease onset in older age.29
In women, there is a peak occurrence between the ages of 20 years
and 35 years, with a second smaller peak between the ages of
45 years and 49 years.30 Estrogen exhibits a neuroprotective role
and may account for the sex difference in schizophrenia.31 Inter-
estingly, it was also proposed that estrogen might improve psori-
asis by inhibiting T cell response and reducing cytokine and
chemokine secretion by keratinocytes.32 Considering the protective
roles of estrogen in both schizophrenia and psoriasis, decreased
estrogen levels may contribute to the onset of schizophrenia in
female psoriatic patients susceptible to schizophrenia in older
age.29,33 Further investigations are required to test this hypothesis.
There were some limitations to this study. First, this is a cross-
sectional study; therefore, the causal relationship between psoria-
sis and schizophrenia could not be determined. Second, the iden-
tiﬁcation of patients relied upon ICD-9-CM codes from the claim
database. Psoriatic patients were deﬁned as enrollees that had been
documented with a code of psoriasis one time or more during the
study period. However, there may be mismatches between coding
and diagnosis. For schizophrenia, the possibility of miscoding was
reduced by using concomitant catastrophic illness certiﬁcates to
deﬁne schizophrenia. Third, we only adjusted for age, gender, and
comorbidities in the statistical analysis. Psoriasis and schizophrenia
are complex diseases, and some confounding factors may not be
included in our analysis.34,35 Medication use, for example, could be
involved in the association between psoriasis and schizophrenia.
The role of medication was not evaluated in our present study.
In conclusion, the prevalence of schizophrenia is higher in male
and female patients with psoriasis. Psoriatic patients with comor-
bid cerebrovascular disease or chronic pulmonary disease have
higher ORs for schizophrenia as compared with psoriatic patients
without these diseases. Although the exact mechanisms remain to
be clariﬁed, psoriatic patients having cerebrovascular disease or
chronic pulmonary disease are likely to have higher disease activity,and, therefore, higher inﬂammatory burden. These factors may
contribute to the development of schizophrenia if a disruption of
the bloodebrain barrier is present. Decreased estrogen levels may
also play a role in the link between psoriasis and schizophrenia.References
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